Right from the opening bell till mid-afternoon now, Jubilant Lifesciences has held strong to its position as the top gainer on the BSE. Intra day, the stock rose over 11% to Rs.380.80 and is now at Rs.370 levels, up over 8%. Its 52-week high is at Rs.455.

As explained in detail in our Market Whispers column – the company has posted very healthy numbers for Q1FY17. Its consolidated OP has risen to Rs. 297 core, up 16% on YoY and 80% sequentially. All the segments have shown healthy performance. Pharma division EBIT is up 77% QoQ at Rs.210 core, Life Sciences Ingredient division EBIT is up 19% at Rs.97 crore and  Drug Discovery division EBIT came in at Rs.12 crore v/s negative EBIT in prior quarters.

OPM has expanded by 980 bps QoQ to 20.9% from 11.1%, leading to PAT of Rs.162 core v/s Rs.48 crore in Q4 and Rs.132 crore in previous Q1, yielding an EPS of Rs.10.15 for Q1.

China has reduced Anti-Dumping Duty on its Pyridine to 17.6% from 24.6% and company is on track to add 2 pyridine derivatives in H2 FY17, while it has received 2 ANDA approvals in Q1 as well, which is seen quite positive.

Its net debt stands at Rs.3,943 crore compared to Rs. 4,190 Crore in March’16, a reduction of Rs.247 crore in current Q1.